Sentinel lymph node biopsy in early breast cancer

Breast Care

Volumn 6, Issue 3, 2011, Pages 185-191

  Kühn, Thorsten ^a  

^a KLINIKUM ESSLINGEN   (Germany)

Author keywords

Axillary lymph node dissection; Breast cancer; Sentinel lymph node biopsy; Surgery

Indexed keywords

ADJUVANT CHEMOTHERAPY; AXILLARY LYMPH NODE; BREAST CANCER; BREAST EXAMINATION; BREAST SURGERY; DISEASE FREE SURVIVAL; FALSE NEGATIVE RESULT; FOLLOW UP; HISTOPATHOLOGY; HUMAN; INTRADUCTAL CARCINOMA; MULTIPLE CANCER; OVERALL SURVIVAL; PATIENT SELECTION; PREGNANT WOMAN; PRIORITY JOURNAL; REVIEW; SENTINEL LYMPH NODE BIOPSY; TUMOR VOLUME;

EID: 79959866807     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000329193     Document Type: Review

References (37)

1. Kim T, Giuliano AE, Lyman GH: Lymphatic mapping and sentinel lymph node biopsy in early stage breast carcinoma: a metaanalysis. Cancer 2006;106:4-16. (Pubitemid 43033320)
2. Veronesi U, Viale G, Paganelli G, et al.: Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled trial. Ann Surg 2010;251:595-600.
3. Krag DN, Anderson SJ, Julian TB, et al.: Sentinel-lymph-node resection compared with conventional axillary lymph node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 2010;11:927-933.
4. van der Ploeg IM, Nieweg OE, van Rijk MC, Valdes Olmos RA, Kroon BB: Axillary recurrence after a tumour-negative sentinel node biopsy in breast cancer patients: A systematic review and meta-analysis of the literature. Eur Surg Oncol 2008;34:1277-1284.
5. Roumen RM, Geuskens LM, Valkenburg JG: In search of the true sentinel node by different injection techniques in breast cancer patients. Eur J Surg Oncol 2000;26:195-196. (Pubitemid 30242949)
6. Kühn T: Clinical aspects of sentinel lymph node biopsy (Expert Discussion). Breast Care 2007; 2:234-239. (Pubitemid 47402762)
7. Kuehn T, Vogl FD, Helms G, Pueckler S, Schirrmeister H, Strueber R, Koretz K, Kreienberg R: Sentinel-node-biopsy is a reliable method for axillary staging in breast cancer: results from a large prospective German multi-institutional trial. Eur J Surg Oncol 2004;30:252-259. (Pubitemid 38425641)
8. Kuehn T, Bembenek A, Decker T, Munz DL, Sautter-Bihl ML, Untch M, Wallwiener D; Consensus Committee of the German Society of Senology: A concept for the clinical implementation of sentinel lymph node biopsy in patients with breast carcinoma with special regard to quality assurance. Cancer 2005;103:451-461.
9. www.ago-online.de.
10. Rubio IT, Aznar F, Lirola J, Peg V, Xercavins J: Intraoperative assessment of sentinel lymph nodes after neoadjuvant chemotherapy in patients with breast cancer. Ann Surg Oncol 2010;17:235-239.
11. Knauer M, Konstantniuk P, Haid A, et al.: Multicentric breast cancer: a new indication for sentinel-node-biopsy-a multicentric validation study. J Clin Oncol 2006;24:3374-3380. (Pubitemid 46638892)
12. Schrenk P, Wayand W: Sentinel-node biopsy in axillary lymph-node staging for patients with multi-centric breast cancer. Lancet 2001;357:122. (Pubitemid 32094920)
13. Specht MC, Fey JV, Borgen PI, Cody HS III: Is the clinically positive axilla in breast cancer really a contraindication to sentinel lymph node biopsy? J Am Coll Surg 2005;200:10-14. (Pubitemid 41583109)
14. Gruber I, Hahn M, Fehm T, Weyhern CH, Stäbler A, Winckelmann A, Wallwiener D, Kühn T: Relevance and methods of interventional breast sonography in preoperative axillary lymph node staging. Eur J Ultrasound 2011, in press.
15. Pandit-Tasker N, Dauer LT, Montgomery L, St Germain J, Zanzonico PB, Divgi CR: Organ and fetal absorbed dose estimates from 99mTc-sulfur colloid lymphoscintigraphy and sentinel node localisation in breast cancer patients. J Nucl Med 2006;47:1202-1208. (Pubitemid 47544916)
16. Untch M, Fasching PA, Konecny GE, et al.: Pathological complete response after neoadjuvant chemotherapy + trastuzumab treatment predicts survival. Fourty one month median follow-up data of the multicenter TECHNO trial. J Clin Oncol 2011, in press.
17. Kuerer HM, Sahin AA, Hunt KK, et al.: Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg 1999;230:72-78. (Pubitemid 30190367)
18. Xing Y, Foy M, Cox DD, et al.: Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br J Surg 2006;93:539-546.
19. Fehm T, Helms G, Banys M, Kuehn T: Management of the axilla for ipsilateral breast cancer recurrence after previous sentinel lymph node biopsy and breast conserving therapy. Gynecol Surg 2011;8:13-18.
20. Nassar A, Cohen C, Cotsonis G, Carlson G: Significance of intramammary lymph nodes in the staging of breast cancer: correlation with tumor characteristics and outcome. Breast 2008;14:147-152. (Pubitemid 351341836)
21. Egan RL, McSweeney MB: Intramammary lymph nodes. Cancer 1983;51:1838-1842. (Pubitemid 13093952)
22. Cody HS 3rd: Clinical significance and management of extra-axillary sentinel lymph nodes: worthwhile or irrelevant? Surg Oncol Clin N Am 2010;19:507-517.
23. Green FL, Page DL, Fleming ID, et al. (eds): AJCC Cancer Staging Manual, ed 6. Chicago, American Joint Commission on Cancer, 2002.
24. Tan LK, Giri D, Hummer AJ, Panageas KS, Brogi E, Norton L, Hudis C, Borgen PI, Cody HS: Occult axillary node metastases in breast cancer are prognostically significant: results in 368 node-negative patients with 20-year follow-up. J Clin Oncol 2008;26:1803-1809.
25. De Boer M, van Deurzen C, van Dijck J, Borm GF, van Diest PJ, Adang EM, Nortier J, Rutgers EJT, Seynaeve C, Menke-Pluymers M, Bult P, Tjan-Heijnen VCG: Micrometastases or isolated tumor cells and the outcome of breast cancer. N Engl J Med 2009;361:653-663.
26. Julian TB, Anderson SJ, Golesorkhi N, Four-chette V, Mamounas EP, Wolmark N: Prospective outcomes for patients with micrometastases and macrometastases in sentinel nodes: NSABP B-32 sentinel node trial. SABCS 2010;abstr S-1.
27. Cserni G, Gregori D, Merletti F, et al.: Metaanaly-sis of non-sentinel node metastases associated with micrometastatic sentinel nodes in breast cancer. Br J Surg 2004;91:1245-1252. (Pubitemid 39331448)
28. Tjan-Heijnen VC, Pepels MJ, de Boer M, et al.: Impact of omission of completion axillary lymph node dissection or axillary therapy in breast cancer patients with micrometastases (pN1mi) or isolated tumor cells (pN0(i+)) in the sentinel lymph node (SN): results from the MIRROR study. Orlando, American Society of Clinical Oncology, 2009, CRA506.
29. Martin M, Pienkowski T, Mackey J: Adjuvant docetaxel for node positive breast cancer. N Engl J Med 2005;352:2302-2313. (Pubitemid 40740554)
30. Roche H, Fumoleau P, Spielmann M, et al.: Sequential adjuvant epirubicin-based and doce-taxel chemotherapy for node positive breast cancer patients: the FNCLCC PACS 01 trial. J Clin Oncol 2006;24:5664-5671. (Pubitemid 46631307)
31. Giuliano AE, McCall L, Beitsch P, Whithworth PW, Blumencranz P, Leitch AM, Saha S, Hunt KK, Morrow M, Ballman K: Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases. Ann Surg 2010;252:426-433.
32. Orr RK: The impact of prophylactic axillary node dissection on breast cancer survival-a Bayesian meta-analysis. Ann Surg 1999;6:109-116. (Pubitemid 29077496)
33. Krag DN, Single RM: Breast cancer survival according to number of nodes removed. Ann Surg Oncol 2003;10:1152-1159. (Pubitemid 40486809)
34. Park J, Fey JV, Naik AM, et al.: A declining rate of completion axillary dissection in sentinel lymph node positive breast cancer patients is associated with the use of a multivariate nomogram. Ann Surg 2007;245:462-468. (Pubitemid 46673143)
35. Kühn T: The role of axillary lymph node dissection in SLN positive patients-are the results of Z11 practice changing? Breast Care 2010;5:431-432.
36. Fisher B, Jeong JH, Anderson S, et al.: Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy and total mastectomy followed by irradiation. N Engl J Med 2002;347:567-575.
37. Moebus V, Jackisch C, Luecvk HJ, et al.: Intense dose-dense sequential chemotherapy with epiru-bicin, paclitaxel and cyclophosphamide compared with conventionally scheduled chemotherapy in high risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol 2010;28:2874-2880.